Article metrics

Download PDFPDF

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)

 

Online download statistics by month:

Online download statistics by month: May 2019 to December 2021

AbstractFullPdf
May 2019449458287
Jun 2019287313146
Jul 201917116075
Aug 201915113568
Sep 201916513973
Oct 201918015965
Nov 201917315065
Dec 201920618677
Jan 202021319767
Feb 202024524378
Mar 202017417445
Apr 202015115144
May 202012712739
Jun 202013613647
Jul 20201059334
Aug 2020828029
Sep 202018517143
Oct 202015814746
Nov 202013112048
Dec 20201029033
Jan 202113412753
Feb 202116014874
Mar 2021898231
Apr 2021887835
May 2021757115
Jun 2021777223
Jul 2021625523
Aug 2021635921
Sep 2021706328
Oct 2021786945
Nov 2021706230
Dec 2021615627
Total461843711814